Regeneron Pharmaceuticals, Inc. REGN
788.04
(7.98)
(1.00%)
as of 25 Sep
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
8,443.60 | 8,605.20 | 8,753.70 | 7,994.60 |
Receivables |
5,687.10 | 5,741.10 | 5,731.00 | 6,565.40 | |
Inventory |
3,254.40 | 3,200.80 | 3,103.60 | 3,084.30 | |
Total current assets |
17,980.70 | 18,021.90 | 18,209.20 | 18,446.00 | |
Property, Plant, Equpment (Net) |
5,002.30 | 5,120.40 | 5,266.10 | 5,458.90 | |
Long-Term Investments |
10,285.70 | 10,260.60 | 9,786.00 | 9,828.30 | |
Goodwill and Intangible Assets (Total) |
1,380.90 | 1,257.40 | 1,286.90 | 1,309.80 | |
Long Term Assets (Tax, Deferred) |
3,846.70 | 4,077.20 | 4,190.90 | 4,381.40 | |
Long-term assets (Other) |
1,673.10 | 1,821.20 | 2,129.70 | 2,306.20 | |
Total non-current assets |
22,188.70 | 22,536.80 | 22,659.60 | 23,284.60 | |
Total Assets |
40,169.40 | 40,558.70 | 40,868.80 | 41,730.60 | |
Accounts Payable |
903.80 | 939.00 | 1,027.10 | 1,159.30 | |
Accrued Expenses |
— | 2,876.40 | — | 2,966.50 | |
Current Part of Capital Lease |
— | 0.00 | 720.00 | 720.00 | |
Current Revenue (Deferred) |
545.60 | 553.00 | 636.20 | 684.80 | |
Other current liabilities |
2,975.70 | 2,876.40 | 2,724.40 | — | |
Total current liabilities |
4,425.10 | 4,368.40 | 5,107.70 | 5,530.60 | |
Long Term Debt (Total) |
2,705.50 | 2,705.90 | 1,986.20 | 1,986.60 | |
Non-current Revenue (Deferred) |
219.20 | 208.70 | 225.10 | 220.40 | |
Non-current Liabilities (Other) |
1,861.80 | 2,018.80 | 2,126.20 | 2,281.60 | |
Total non-current liabilities |
4,786.50 | 4,933.40 | 4,337.50 | 4,488.60 | |
Total liabilities |
9,211.60 | 9,301.80 | 9,445.20 | 10,019.20 | |
Additional Paid In Capital |
13,787.30 | 13,995.00 | 14,401.30 | 14,700.60 | |
Common Stock (Net) |
0.10 | 0.10 | 0.10 | 0.10 | |
Retained Earnings |
35,045.80 | 35,797.10 | 36,423.80 | 37,621.40 | |
Treasury Stock |
17,944.40 | 18,612.80 | 19,413.50 | 20,574.90 | |
Common Equity (Total) |
30,957.80 | 31,256.90 | 31,423.60 | 31,711.40 | |
Shareholders Equity (Total) |
30,957.80 | 31,256.90 | 31,423.60 | 31,711.40 | |
Shareholders Equity and Liabilities (Total) |
40,169.40 | 40,558.70 | 40,868.80 | 41,730.60 | |
Shares (Common) |
105.30 | 103.90 | 105.00 | 101.60 | |
Shareholders Equity (Tangible) |
29,576.90 | 29,999.50 | 30,136.70 | 30,401.60 | |
Net Debt |
(5,738.10) | (5,899.30) | (6,767.50) | (6,008.00) | |
Total Debt |
2,705.50 | 2,705.90 | 1,986.20 | 1,986.60 |
In millions of $ except per-share values · columns are period end dates